Novo Nordisk (NVO) or Eli Lilly (LLY)? Jim Cramer Gives a Clear Response

What happened: On Mad Money's October 1 lightning round, Jim Cramer said he would stay with Eli Lilly over Novo Nordisk for three to five years, calling Lilly a high quality stock and citing CEO Dave Ricks. Key numbers: Lilly Q2 revenue about $23 billion, up 48% year over year. Mounjaro revenue up 91% to about $9.9 billion. U.S. Zepbound sales up 44% to about $4.9 billion. Why it matters: Cramer's preference favors Lilly despite Novo's lower valuation. Novo's full-year outlook still ranges from flat to a 6% decline, and it recorded DKK6.3 billion in impairment charges. Market: +0.8% by next close ($1,179.27 on Oct 9), +12.4% YTD

On Mad Money's October 1 lightning round, Jim Cramer said he would stay with Eli Lilly over Novo Nordisk for three to five years, calling Lilly a high quality stock and citing CEO Dave Ricks.

Cramer's preference favors Lilly despite Novo's lower valuation. Novo's full-year outlook still ranges from flat to a 6% decline, and it recorded DKK6.3 billion in impairment charges. Market: +0.8% by next close ($1,179.27 on Oct 9), +12.4% YTD